Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795982 | 1.00 | CHRM2 (0.36) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL6651067 | 0.83 | PPM1D (0.32) | — | |
| SCHEMBL6657793 | 0.83 | PPM1D (0.32) | — | |
| SCHEMBL27547776 | 0.83 | PPM1D (0.32) | — | |
| SCHEMBL7769821 | 0.82 | CHRM2 (0.32) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL15498623 | 0.82 | CHRM3 (0.32) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL28296372 | 0.80 | CYP19A1 (0.37) | CHRM2CHRM1CHRM3ATMCYP19A1 | |
| SCHEMBL17886845 | 0.78 | CYP19A1 (0.41) | CHRM3ATMCYP19A1 | |
| SCHEMBL13563625 | 0.78 | RIPK1 (0.34) | CHRM2CHRM1CHRM3 | |
| SCHEMBL15706272 | 0.77 | CHRM2 (0.30) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3227297-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
| US-20190177328-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
| US-20170362240-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
| US-10189845-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | CHRM2 3835/4885CHRM1 3061/4885CHRM3 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.